公开(公告)号：US20190177383A1

公开(公告)日：2019-06-13

申请号：US16281790

申请日：2019-02-21

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Helen HOERZER ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/47 ,  C07K16/30 ,  C07K14/705 ,  A61K35/17 ,  G01N33/569 ,  C12P21/02 ,  C12Q1/6881 ,  C07K16/32 ,  G01N33/574 ,  C12Q1/6886 ,  C12N5/0783 ,  C07K16/28 ,  C07K7/06 ,  C07K7/08 ,  C12N15/115 ,  A61K39/00 ,  C07K14/74 ,  C07K16/18 ,  C07K14/82

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190177368A1

公开(公告)日：2019-06-13

申请号：US16283528

申请日：2019-02-22

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Steffen Walter ,  Jens Fritsche ,  Colette Song ,  Harpreet Singh

IPC: C07K7/08 ,  A61K39/00 ,  C07K7/06 ,  C12N5/0783 ,  C12N9/64 ,  A61K38/17

Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

公开(公告)号：US20190091311A1

公开(公告)日：2019-03-28

申请号：US16210330

申请日：2018-12-05

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Phillip MUELLER ,  Julia LEIBOLD ,  Valentina GOLDFINGER

IPC: A61K39/00 ,  G01N33/574 ,  G01N33/68 ,  C07K14/47 ,  C07K14/725 ,  C12N15/115 ,  C07K16/30 ,  C12N5/0783 ,  C12Q1/6886 ,  A61K38/00

CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/30 ,  C07K2319/00 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57407 ,  G01N33/5748 ,  G01N33/6848 ,  G01N2570/00 ,  G01N2800/52

Abstract: A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.

公开(公告)号：US20190040115A1

公开(公告)日：2019-02-07

申请号：US16167656

申请日：2018-10-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Annika SONNTAG ,  Toni WEINSCHENK ,  Andrea MAHR ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  G06F19/20 ,  C12N5/0783 ,  A61K38/17 ,  A61K39/00 ,  C07K14/725 ,  C07K16/28 ,  A61K35/17 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: C07K14/70539 ,  A61K35/17 ,  A61K38/04 ,  A61K38/1709 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55588 ,  A61P35/00 ,  A61P37/04 ,  C07K7/06 ,  C07K14/7051 ,  C07K16/2833 ,  C12N5/0636 ,  C12N5/0638 ,  C12N15/115 ,  C12N2310/16 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/57484 ,  G01N2333/70539 ,  G16B25/00

Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.

公开(公告)号：US20190008937A1

公开(公告)日：2019-01-10

申请号：US16138655

申请日：2018-09-21

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Oliver SCHOOR ,  Andrea MAHR

IPC: A61K39/00 ,  C07K16/00 ,  C07K14/64 ,  C07K14/47 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68 ,  G06F19/20 ,  C07K14/705

CPC classification number: A61K39/0011 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K14/4743 ,  C07K14/64 ,  C07K14/70503 ,  C07K14/7051 ,  C07K16/00 ,  C07K16/18 ,  C07K16/2809 ,  C07K2319/40 ,  C12N5/0638 ,  C12N15/115 ,  C12N2310/16 ,  C12Q1/6886 ,  C12Q2600/136 ,  G01N33/57484 ,  G01N33/6872 ,  G01N2333/70539 ,  G16B25/00

Abstract: The present description relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180360936A1

公开(公告)日：2018-12-20

申请号：US16106951

申请日：2018-08-21

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C12N15/115 ,  C07K14/72 ,  G01N33/574 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  C07K14/725 ,  C07K14/71 ,  C12N9/12 ,  C12N9/02 ,  C12N5/0783 ,  G06F19/20 ,  C12Q1/6886 ,  C07K16/40 ,  C07K16/38 ,  C07K16/30 ,  C07K16/28 ,  C07K16/18 ,  C07K14/81 ,  A61K38/00 ,  A61K35/17

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/71 ,  C07K14/721 ,  C07K14/8135 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/2869 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/0091 ,  C12N9/1264 ,  C12N15/115 ,  C12N2310/16 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Y116/01 ,  C12Y207/07031 ,  G01N33/57484 ,  G01N2333/47 ,  G06F19/20

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180327474A1

公开(公告)日：2018-11-15

申请号：US16027993

申请日：2018-07-05

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  G01N33/574 ,  A61K39/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/50 ,  C12Q1/6886

CPC classification number: C07K14/70539 ,  A61K38/1764 ,  A61K39/0011 ,  A61K39/00111 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/34 ,  C07K2319/70 ,  C07K2319/74 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/505 ,  G01N33/574 ,  G01N2333/70539

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180303921A1

公开(公告)日：2018-10-25

申请号：US16024164

申请日：2018-06-29

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Helen HOERZER ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  A61K38/17 ,  C07K7/06 ,  C07K14/47 ,  C07K14/725 ,  C07K16/28 ,  C12N15/115 ,  A61P35/02

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/08 ,  A61K38/1709 ,  A61K2039/5158 ,  A61P35/02 ,  C07K7/06 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/00 ,  C07K16/2833 ,  C07K2317/41 ,  C12N15/115 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180251518A1

公开(公告)日：2018-09-06

申请号：US15971799

申请日：2018-05-04

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  A61K39/00 ,  C12N5/0783 ,  C07K14/47 ,  G01N33/569 ,  C12N9/64 ,  C07K14/00 ,  G01N33/50 ,  A61K38/17 ,  C07K16/28 ,  A61K45/06 ,  C07K14/725 ,  C12Q1/6886 ,  C07K16/30 ,  C07K7/06 ,  C07K7/02 ,  A61K38/08 ,  G01N33/566 ,  C07K16/18

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180207251A1

公开(公告)日：2018-07-26

申请号：US15869471

申请日：2018-01-12

Applicant: immatics biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C12N15/115 ,  C07K16/18 ,  C07K14/74 ,  C07K14/47

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K39/001174 ,  A61K2039/5158 ,  C07K14/4748 ,  C07K14/70539 ,  C07K16/18 ,  C07K2319/00 ,  C12N15/115 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.